A bill for an act relating to insurance coverage for prescription drugs used in the treatment of metastatic cancer and associated conditions.
Senate File 197 would require certain health insurance policies, health maintenance organization contracts, and public employee health plans that cover prescription drugs to also cover prescription cancer drugs used to treat metastatic cancer and related associated conditions. The bill defines metastatic cancer, prescription cancer drug, associated conditions, and related terms, and it directs coverage for these drugs when they are medically necessary, consistent with medical standards of care, supported by peer-reviewed evidence-based literature, and approved by the U.S. Food and Drug Administration.
The bill also prohibits insurers from imposing step therapy protocols on qualifying prescription cancer drugs. In other words, covered persons could not be required to try other drugs first before receiving the prescribed cancer treatment if the drug meets the bill’s criteria. The mandate would apply to specified insurance products delivered, issued, continued, or renewed in Iowa on or after January 1, 2026, while excluding several categories of coverage such as accident-only, short-term, Medicare supplement, dental, vision, workers’ compensation, and similar limited-benefit plans. The insurance commissioner is authorized to adopt rules to administer the new requirements.
SF 197 would amend Iowa insurance law by creating a new coverage mandate in chapter 514C for prescription drugs used to treat metastatic cancer and associated conditions. It would require affected insurers and health plans to cover qualifying cancer drugs and would override conflicting uniformity-of-treatment requirements and step therapy provisions for those drugs. The bill would affect individual and group health insurance, hospital and medical service contracts, HMOs, and public employee health plans, while leaving exempted policy types unchanged. The commissioner of insurance would gain rulemaking authority to implement the law.
The available context suggests generally favorable treatment of the bill, as the subcommittee recommended passage and there is no recorded vote opposition or committee transcript indicating controversy. The bill’s structure and exclusions suggest it was drafted as a targeted patient-protection measure focused on access to cancer treatment rather than a broad insurance overhaul. Overall, the legislative posture appears supportive and noncontentious at the subcommittee stage.
The main policy tension in SF 197 is between patient access to metastatic cancer drugs and insurer utilization-management tools, especially step therapy. Supporters would likely view the bill as ensuring timely access to medically necessary cancer treatment, while insurers or plan administrators could be concerned about reduced flexibility in managing costs and treatment sequencing. Another possible point of contention is the scope of the mandate, including which plans are covered, the requirement that drugs be FDA-approved and evidence-based, and the bill’s effective date for policies renewed on or after January 1, 2026.